Welcome to our dedicated page for Kazia Therapeuti news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeuti stock.
Kazia Therapeutics Limited develops clinical-stage oncology therapies through an Australian foreign-issuer structure whose American depositary shares trade under KZIA. Company news centers on paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor being developed across brain cancer and advanced breast cancer indications, including triple-negative breast cancer studies that report clinical and translational findings.
Recurring updates also cover Kazia's broader oncology platform, including NDL2, a PD-L1 protein degrader platform, and MSETC, a SETDB1-targeted epigenetic program. Additional company developments include research leadership, licensing activity, financing and capital-structure actions, Nasdaq listing compliance, annual meeting matters, governance changes, and operating or financial results.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announces the opening of the GBM AGILE study in glioblastoma at Sunnybrook Health Sciences Centre in Toronto, marking Canada's first site for paxalisib recruitment. This expansion into Canada allows Canadian patients to access potential new treatment options for glioblastoma, which affects approximately 1,200 Canadians annually. The study aims to enroll up to 200 patients on paxalisib and will include sites in the US, with plans to expand to Europe and China in the coming months.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced the appointment of John Friend, MD, as Chief Medical Officer. Dr. Friend will lead the development and commercialization of Kazia's oncology drug pipeline, including paxalisib and EVT801. With over 25 years of experience, Dr. Friend previously served as CMO at Cellectar Biosciences and held senior positions at Helsinn Therapeutics. His expertise is expected to enhance Kazia's research initiatives, especially as paxalisib advances toward commercialization.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced the initiation of the PNOC022 study at the University of California, San Francisco, focusing on DIPG and diffuse midline gliomas, with the first patient successfully enrolled. This phase II study will investigate the efficacy of Kazia's investigational drug, paxalisib, in various treatment arms. DIPG is a highly aggressive childhood brain cancer with no FDA-approved treatments. The study aims to recruit several hundred patients and will utilize novel trial designs to explore combination therapies, making it a significant step in pediatric oncology.
Kazia Therapeutics Limited (KZIA) has commenced patient enrollment for a Phase I clinical trial of EVT801, an investigational cancer therapy. Licensed from Evotec SE in April 2021, EVT801 targets VEGFR3 to inhibit lymphangiogenesis, showing promising preclinical results. The trial aims to assess safety, tolerability, and pharmacokinetics while exploring preliminary efficacy signals through biomarker analyses. The study will recruit up to 60 patients at the IUCT-Oncopole in Toulouse, France, focusing on renal cell carcinoma and soft-tissue sarcoma. Kazia anticipates further updates as the trial progresses.
Kazia Therapeutics anticipates releasing critical data from its paxalisib program in Q4 2021, including results from a 30-patient Phase II trial for newly diagnosed glioblastoma multiforme and initial data for treating brain metastases. The company has raised its valuation to US$277 million or US$20.92 per basic ADR, which reflects a forward adjustment in its NPV, despite lower net cash of US$20.4 million as of June 30, 2021. Kazia's financing requirement has increased to US$44 million, driven by heightened R&D expenditure.
Kazia Therapeutics Limited (NASDAQ: KZIA) will present at the LD Micro Main Event from October 12-14, 2021. CEO Dr. James Garner will discuss significant developments in 2021, including three cross-border licensing deals and the start of an international pivotal study for its lead asset, paxalisib. The hybrid event will feature around 120 companies, with the Kazia presentation scheduled for 10 AM ET on October 12. Registration for the conference is complimentary and available through the conference website.
Kazia Therapeutics Limited (NASDAQ: KZIA) will present at the HC Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Dr. James Garner will discuss the company's pivotal study on paxalisib, aimed at treating glioblastoma, which affects over 12,500 patients annually. The market potential for this treatment is valued at US$ 1.5 billion. Significant developments include an out-licensing deal for pazalisib in Greater China and in-licensing of another oncology asset, EVT801. Dr. Garner will also outline Kazia's objectives for FY2022.
Kazia Therapeutics Limited (NASDAQ: KZIA) highlights Glioblastoma (GBM) Awareness Day on July 21, 2021, urging increased research focus on this aggressive brain cancer, which affects around 13,000 Americans annually. Current GBM treatments yield limited benefits, with median survival at 16 months. CEO Dr. James Garner expresses confidence in future treatment advancements, particularly with the drug paxalisib, currently in phase II trials. Kazia calls for collaboration among stakeholders to improve GBM treatment prospects.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) provided an update on its oncology pipeline, focusing on paxalisib and EVT801. The GBM AGILE study for paxalisib is recruiting nearly 25 sites ahead of schedule in the U.S., with over 650 patients screened to date. The phase II study of paxalisib has seen its final patient complete treatment, while the phase I study of EVT801 has submitted its protocol to French regulators. Kazia anticipates upcoming data releases from ongoing studies in 2021.
Kazia Therapeutics Limited (NASDAQ: KZIA) has initiated a collaboration with Weill Cornell Medical College for a Phase II clinical trial examining paxalisib combined with a ketogenic diet for glioblastoma treatment. This study aims to explore the potential of ketogenesis in enhancing paxalisib's effectiveness and reducing side effects like hyperglycemia. Led by Dr. Howard Fine, the trial will consist of two arms, with an initial cohort of 16 patients in each. Recruitment is expected to start by the end of 2021, pending regulatory approvals.